Jane Liesveld, MD
Hematology · Rochester, NYNPI 1851319610
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,014 of the $43,331 with a category attached, or 80.8%. 11 manufacturers reported payments, led by Servier Pharmaceuticals LLC at 46.4% of the total. Reporting peaked in 2023 at $16,293 and has fallen 79.4% since, to $3,363 in 2025.
Across 55 payments — averaging $787.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Servier Pharmaceuticals LLC$20K
- Merck$7K
- National Marrow Donor Program$5K
- Novartis$3K
- Blueprint Medicines Corporation$3K
- Bristol Myers Squibb$2K
- plus $4K from 5 others
Across 215 payments — averaging $6847.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$508K
- Pfizer$430K
- Taiho Oncology, Inc.$191K
- Otsuka Pharmaceutical Co., Ltd.$95K
- Janssen Research & Development, LLC$58K
- Incyte Corporation$55K
- plus $134K from 9 others
What the payments were for
- Consulting fees$35,01481%
- Speaking & faculty fees$4,73311%
- Travel & lodging$2,3936%
- Food & beverage$1,1923%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Servier Pharmaceuticals LLC | 20 | $20,101 |
| Merck | 9 | $6,500 |
| National Marrow Donor Program | 13 | $5,000 |
| Novartis | 1 | $2,763 |
| Blueprint Medicines Corporation | 1 | $2,633 |
| Bristol Myers Squibb | 2 | $2,141 |
| Daiichi Sankyo Inc. | 1 | $1,935 |
| Pharmacosmos Therapeutics Inc. | 1 | $1,500 |
| Jazz Pharmaceuticals Inc. | 5 | $597 |
| Gilead | 1 | $112 |
| Biolinerx USA, Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,331 in reported general payments places this provider in the 85th percentile of 157 hematology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 96 | $1,277,651 |
| RezurockBelumosudil Mesylate | 32 | $1,125,945 |
| Lenalidomide | 34 | $508,176 |
| CalquenceAcalabrutinib Maleate | 27 | $489,618 |
| InqoviDecitabine/Cedazuridine | 17 | $138,528 |
| VenclextaVenetoclax | 25 | $107,886 |
| Imatinib Mesylate | 35 | $85,440 |
| EliquisApixaban | 11 | $7,147 |
| Fluconazole | 58 | $4,102 |
| Acyclovir | 91 | $1,326 |
| Voriconazole | 13 | $1,262 |
| Tacrolimus | 18 | $604 |
| ValacyclovirValacyclovir Hcl | 19 | $505 |
| Pantoprazole Sodium | 37 | $284 |
| Famotidine | 26 | $226 |
Paid to pharmacies, not to this prescriber.
Other hematology in Rochester
- Paul BarrRochester$111K
- Carla CasuloRochester$43K
- Kah Poh LohRochester$9K
- Jonathan FriedbergRochester$6K
- Jason MendlerRochester$6K
- Ajay DhakalRochester$5K
- Andrew EvansRochester$5K
- Barry CollerNew York$7.9M
- Allyson OceanNew York$1.4M
- Ahmed SawasNew York$618K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.